Diamyd Medical’s patent protection extended to 2032 in pivotal decision

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that The Regents of the University of California on behalf of its Los Angeles Campus (UCLA) has been granted another key US patent for its GAD65 technology on which the Diamyd® diabetes vaccine is based. The term of the new patent runs into 2032, which is approximately 10 years longer than current US patents. Diamyd Medical is the exclusive licensee to the new patent.The Diamyd® diabetes vaccine is an Antigen Based Therapy (ABT) under development for the treatment and prevention of autoimmune diabetes. The active